NVO Novo Nordisk A/S

$59.67

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About Novo Nordisk A/S

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Website: https://www.novonordisk.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
353278
Address
NOVO ALLE DK 2880, BAGSVAERD DENMARK, DK
Valuation
Market Cap
$285.37B
P/E Ratio
16.98
PEG Ratio
0.86
Price to Book
11.88
Performance
EPS
$3.42
Dividend Yield
2.78%
Profit Margin
34.80%
ROE
80.80%
Technicals
50D MA
$77.10
200D MA
$105.50
52W High
$145.26
52W Low
$57.28
Fundamentals
Shares Outstanding
3B
Target Price
$101.52
Beta
0.25

NVO EPS Estimates vs Actual

● Estimated
● Actual

NVO News & Sentiment

Oct 06, 2025 • Benzinga SOMEWHAT-BULLISH
Eli Lilly Plans To Spend $1B In India To Expand Manufacturing - Eli Lilly ( NYSE:LLY )
Eli Lilly and Co. ( NASDAQ:LLY ) plans to invest over $1 billion in India to strengthen its manufacturing network, according to Reuters. The move aims to tap into the country's skilled workforce and support Lilly's global expansion.
Oct 06, 2025 • Benzinga NEUTRAL
Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss - Skye Bioscience ( NASDAQ:SKYE )
Skye Bioscience Inc. ( NASDAQ:SKYE ) stock sank on Monday after the company released topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab. The nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo ( -1.52% vs. -0.26 for ...
Oct 06, 2025 • Motley Fool SOMEWHAT-BULLISH
Eli Lilly: Beyond Weight Loss
Eli Lilly is riding a big trend.
Oct 06, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk
Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.
Oct 05, 2025 • Motley Fool SOMEWHAT-BULLISH
2 Beaten-Down Stocks Primed for a Comeback
The market is sleeping on these stocks, but you don't have to.
Oct 04, 2025 • Motley Fool SOMEWHAT-BULLISH
4 Reasons to Buy Amgen Stock Right Now
For those with a sufficiently long investment horizon, the stock looks attractive.
Sentiment Snapshot

Average Sentiment Score:

0.163
50 articles with scored sentiment

Overall Sentiment:

Bullish

NVO Reported Earnings

Feb 05, 2025
Dec 31, 2024 (Pre market)
0.23 Surprise
  • Reported EPS: $6.34
  • Estimate: $6.12
  • Whisper: —
  • Surprise %: 3.7%
Nov 06, 2024
Sep 30, 2024 (Pre market)
0.02 Surprise
  • Reported EPS: $0.90
  • Estimate: $0.88
  • Whisper: —
  • Surprise %: 2.3%
Aug 07, 2024
Jun 30, 2024 (Pre market)
-0.08 Surprise
  • Reported EPS: $0.66
  • Estimate: $0.74
  • Whisper: —
  • Surprise %: -10.4%
May 02, 2024
Mar 31, 2024 (Pre market)
0.06 Surprise
  • Reported EPS: $0.83
  • Estimate: $0.77
  • Whisper: —
  • Surprise %: 7.8%
Jan 31, 2024
Dec 31, 2023 (Pre market)
0.05 Surprise
  • Reported EPS: $0.71
  • Estimate: $0.66
  • Whisper: —
  • Surprise %: 7.6%
Nov 02, 2023
Sep 30, 2023 (Pre market)
0.04 Surprise
  • Reported EPS: $0.73
  • Estimate: $0.69
  • Whisper: —
  • Surprise %: 5.8%
Aug 10, 2023
Jun 30, 2023 (Pre market)
0.04 Surprise
  • Reported EPS: $0.67
  • Estimate: $0.63
  • Whisper: —
  • Surprise %: 6.3%
May 04, 2023
Mar 31, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $0.63
  • Estimate: $0.61
  • Whisper: —
  • Surprise %: 3.3%
Feb 01, 2023
Dec 31, 2022 (Pre market)
-0.02 Surprise
  • Reported EPS: $0.41
  • Estimate: $0.43
  • Whisper: —
  • Surprise %: -5.3%

Financials